The effects of chronic usage of enzyme inhibitors and angiotensin receptor blockers on contrast-induced nephropathy in low-risk patients;Düşük riskli hastalarda anjiyotensin dönüştürücü enzim inhibitörleri ve anjiyotensin reseptör blokerlerinin kronik kullanımının kontrast madde nefropatisi üzerine etkileri

Anadolu Kardiyoloji Dergisi

Volumn 13, Issue 3, 2013, Pages 245-250

  Bariş, Nezihi ^a   Özpelit, Ebru ^a   Bilgin Doǧan, Nazile ^a   Kangül, Hande ^a   Gül, Sefa ^a   Akdeniz, Bahri ^a   Güneri, Sema ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Contrast induced nephropathy; Regression analysis

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IODIXANOL; IOPROMIDE; IOXAGLIC ACID; RENIN INHIBITOR;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CHRONIC DRUG ADMINISTRATION; COHORT ANALYSIS; CONTRAST INDUCED NEPHROPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT;

EID: 84877593230     PISSN: None     EISSN: 13080032     Source Type: Journal    
DOI: 10.5152/akd.2013.050     Document Type: Article

References (20)

1. Pucelikova T, Dangas G, Mehran R. Contrast-induced nephropathy. Catheter Cardiovasc Interv 2008; 71: 62-72. [CrossRef]
2. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-64. [CrossRef]
3. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-75. [CrossRef]
4. Toprak O, Cirit M, Bayata S, Yeşil M, Aslan SL. The effect of preprocedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography. Anadolu Kardiyol Derg 2003; 3: 98-103.
5. Cirit M, Toprak O, Yeşil M, Bayata S, Postaci{dotless} N, Pupim L, et al. Angiotensin-converting enzyme inhibitors as a risk factor for contrastinduced nephropathy. Nephron Clin Pract 2006; 104: 20-7. [CrossRef]
6. Komenda P, Zalunardo N, Burnett S, Love J, Buller C, Taylor P, et al. Conservative outpatient renoprotective protocol in patients with low GFR undergoing contrast angiography: a case series. Clin Exp Nephrol 2007; 11: 209-13. [CrossRef]
7. Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK. Captopril for prevention of contrast-induced nephropathy in diabetic patients; a randomized study. Indian Heart J 1999; 51: 521-6.
8. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005; 95: 13-9. [CrossRef]
9. Gault MH, Longerich LL, Harnett JD, Wesolowski C. Predicting glomerular function from adjusted serum creatinine. Nephron 1992; 62: 249-56. [CrossRef]
10. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast induced nephropathy after coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1393-9. [CrossRef]
11. Özcan EE, Güneri S, Akdeniz B, Akyi{dotless}ldi{dotless}z IZ, Şenaslan O, Bari{dotless}ş N, et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J 2007; 154: 539-44. [CrossRef]
12. The ad-hoc working group of ERBP: Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant 2012; 27: 4263-72.
13. Wi J, Ko YG, Shin DH, Kim JS, Kim BK, Choi D, et al. Prediction of contrast-induced nephropathy with persistent renal dysfunction and adverse long-term outcomes in patients with acute myocardial infarction using the mehran risk score. Clin Cardiol 2012 Oct 1. doi: 10.1002/clc.22060. [CrossRef]
14. Hölscher B, Heitmeyer C, Fobker M, Breithardt G, Schaefer RM, Reinecke H. Predictors for contrast-induced nephropathy and longterm survival: prospectively assessed data from the Dialysis-Versus-Diuresis (DVD) trial. Can J Cardiol 2008; 24: 845-50. [CrossRef]
15. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin-converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001; 104: 1985-91. [CrossRef]
16. Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, et al. The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol 2008; 40: 749-55. [CrossRef]
17. Onuigbo MAC, Onuigbo NTC. Does renin-angiotensin aldosterone system blockade exacerbate contrast-i{dotless}nduced nephropathy in patients with chronic kidney disease? A prospective 50-month Mayo Clinic study. Renal Failure 2008; 30: 67-72. [CrossRef]
18. Louis BM, Hoch BS, Hernandez C, Namboodiri N, Neiderman G, Nissenbaum A, et al. Protection from the nephrotoxicity of contrast dye. Renal Failure 1996; 18: 639-46. [CrossRef]
19. Patel K, King CA, Jovin IS. Angiotensin-converting enzyme inhibitors and their effects on contrast-induced nephropathy after cardiac catheterization or percutaneous coronary intervention. Cardiovasc Revasc Med 2011; 12: 90-3. [CrossRef]
20. Kiski D, Stepper W, Brand E, Breithardt G, Reinecke H. Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-Versus-Diuresis (DVD) trial. Nephrol Dial Transplant 2010; 25: 759-64. [CrossRef]